Pomalidomide

Pomalidomide 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Multiple Myeloma、Smoldering Multiple Myeloma、Immunoglobulin Light-chain Amyloidosis、Relapsed Refractory Multiple Myeloma (RRMM)。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。

正在招募患者的 Pomalidomide 研究

• Inobrodib, Pomalidomide and Dexamethasone Versus Standard Available Therapy in Relapsed or Refractory Multiple Myeloma

  III 期招募中美国NCT07772024

• A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments

  I 期 / II 期招募中美国Argentina澳大利亚BrazilNCT05714839

• Zn-DDC to Target Hypoxia-NFkappaB-CSCs Pathway in Multiple Myeloma

  不适用招募中英国NCT04234022

• The Study of the Combination of Thiotepa and Pomalidomide for the Treatment of Relapsed/Refractory Primary Central Nervous System Lymphoma Patients.

  II 期招募中中国NCT05931328

• Pomalidomide After CAR T-cell Therapy for the Treatment of Relapsed or Refractory CD19+ B-cell Leukemia or Lymphoma

  I 期招募中美国NCT07532525

• A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)

  I 期 / II 期招募中美国澳大利亚比利时法国NCT06953960

• Hypofractionated Radiotherapy Plus GM-CSF, Pomalidomide and Glofitamab for Newly Diagnosed PCNS-DLBCL

  II 期招募中中国NCT07749365

• Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma

  II 期招募中美国NCT05208307

• A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients

  III 期招募中中国NCT06508983

• A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)

  III 期招募中中国NCT06464991

• MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

  III 期招募中美国Argentina澳大利亚比利时NCT06152575

• Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma

  III 期招募中美国澳大利亚Brazil加拿大NCT07555938

• A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma

  II 期招募中美国NCT04661137

• A Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing the Efficacy and Safety of F182112 Versus Standard of Care in Patients With Relapsed or Refractory Multiple Myeloma

  III 期招募中中国NCT07579234

• Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse

  II 期招募中美国NCT06948084

• AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma

  I 期 / II 期招募中美国澳大利亚Brazil加拿大NCT06106945

• A Study in Participants With Relapsed or Refractory Multiple Myeloma for IBI3003

  III 期招募中中国NCT07623798

• A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies

  I 期招募中美国NCT04830137

• Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

  I 期 / II 期招募中美国法国西班牙瑞典NCT04068597

• KPD Consolidation After ASCT in NDMM Patients

  II 期 / III 期招募中中国NCT06879379

• A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

  III 期招募中美国澳大利亚BrazilChileNCT07222761

• Cevostamab in Combination With Pomalidomide and Dexamethasone After BCMA- Targeting CAR T-Cell Therapy in Participants With Previously Treated Multiple Myeloma

  II 期招募中德国NCT07825064

• A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma

  I 期招募中美国加拿大法国西班牙NCT05651932

• Daratumumab for Patients With Light Chain Amyloidosis

  不适用招募中中国NCT06376214

本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。